Proprietary XmAb® Engineering Platform: Xencor's core competitive advantage lies in its proprietary XmAb® technology platform, which uses Fc domain engineering to create novel antibodies and Fc fusion proteins with enhanced properties such as extended half-life, improved immune cell killing, or reduced immune response.

Diverse and Advanced Pipeline: The company boasts a robust pipeline of both wholly-owned and partnered product candidates across various stages of development, targeting oncology, autoimmune diseases, and other severe conditions, which diversifies risk and offers multiple shots on goal.

Strategic Partnership Model: Xencor's strategy of forging multiple high-value collaborations with leading pharmaceutical companies (e.g., Amgen, Novartis, Johnson & Johnson) validates its technology, provides significant non-dilutive funding, and leverages partners' global development and commercialization capabilities.